Dapagliflozin reduced the risk of cardiovascular death or worsening heart failure similarly in patients with (HR 0.82; 95% CI 0.62-1.10) and without (HR 0.82; 95% CI 0.72-0.93) mild-to-moderate COPD.
RCT (n=6,261)
Does dapagliflozin reduce cardiovascular death or worsening heart failure in patients with HFmrEF/HFpEF regardless of mild-to-moderate COPD status?
Dapagliflozin consistently reduces the risk of cardiovascular death or worsening heart failure in patients with HFmrEF/HFpEF, regardless of the presence of mild-to-moderate COPD.
Effect estimate: HR 0.82 (95% CI 0.62-1.10)
p-value: pinteraction = 0.98
ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes. In a pre-specified analysis of DELIVER, we investigated the relationship between COPD status and outcomes, and the efficacy and safety of dapagliflozin, compared with placebo, according to COPD status. Methods and results Patients with severe pulmonary disease (including COPD) were excluded from the trial. The primary outcome was a composite of cardiovascular death or worsening heart failure. Of the 6261 patients with data on baseline COPD status, 694 (11.1%) had a known history of this condition. The risk of the primary endpoint was higher in patients with mild-to-moderate COPD compared with those without COPD (adjusted hazard ratio HR 1.28, 95% confidence interval CI 1.08–1.51). The benefit of dapagliflozin on the primary outcome was consistent irrespective of COPD status (no COPD: HR 0.82 95% CI 0.72–0.93; COPD: HR 0.82 95% CI 0.62–1.10; pinteraction = 0.98). Consistent effects were observed for heart failure, cardiovascular, and all-cause hospitalization, and deaths, and composites of these. Dapagliflozin, as compared with placebo, improved the Kansas City Cardiomyopathy Questionnaire scores from baseline to 8 months to a similar extent in patients with and without mild-to-moderate COPD (pinteraction ≥ 0.63). Adverse events and treatment discontinuation were not more frequent with dapagliflozin than with placebo irrespective of COPD status. Conclusions Mild-to-moderate COPD is common in patients with HFmrEF/HFpEF and is associated with worse outcomes. The beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, regardless of COPD status. Clinical Trial Registration: ClinicalTrials.gov NCT03619213.
Butt et al. (2023) conducted an RCT in Heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) (n=6,261). Dapagliflozin vs. Placebo was evaluated on Composite of cardiovascular death or worsening heart failure (HR 0.82, 95% CI 0.62-1.10, p=pinteraction = 0.98). Dapagliflozin reduced the risk of cardiovascular death or worsening heart failure similarly in patients with (HR 0.82; 95% CI 0.62-1.10) and without (HR 0.82; 95% CI 0.72-0.93) mild-to-moderate COPD.